Stocks Health care ARWR
NASDAQ · Health careArrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. brought in $669.5M of revenue over the twelve months to June 30, 2026, up 16.8% from a year earlier. It posted a net loss of $320M. Operating cash flow minus capital spending left $156.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $54.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Arrowhead Pharmaceuticals, Inc.
- Net worth
- Arrowhead Pharmaceuticals, Inc. has a market value (market cap) of $6.9B at the latest share price, and shareholders' equity of $465.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $829.4M (+23,258.2% year on year), with a net loss of $1.6M. Over the 12 months to June 30, 2026: revenue $669.5M, net loss $320M.
- Cash flow
- In fiscal 2025 operations brought in $179.6M of cash; after $22.7M of capital spending, free cash flow was $156.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Arrowhead Pharmaceuticals, Inc.'s next report is expected around November 24, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Arrowhead Pharmaceuticals, Inc. does
Arrowhead Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARWR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $829.4M | -$1.6M | -$0.01 | $156.9M |
| 2024 | $3.6M | -$599.5M | -$5.00 | -$604.3M |
| 2023 | $240.7M | -$205.3M | -$1.92 | -$330.6M |
| 2022 | $243.2M | -$176.1M | -$1.67 | -$188.9M |
| 2021 | $138.3M | -$140.8M | -$1.36 | $147.7M |
| 2020 | $88M | -$84.6M | -$0.84 | -$107.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ARWR ranks in Health care
Latest SEC filings
What Arrowhead Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 171% to $75.3M versus the same quarter last year; diluted EPS -$1.36 versus -$1.26.
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 16, 2026
- May 7, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 86% to $73.7M versus the same quarter last year; diluted EPS -$0.93 versus $2.75.
What is ARWR worth? A DCF from its reported cash flow
Insider trades
What the people running Arrowhead Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.2M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 18, 2026 | Olukotun Adeoye YDirector | Sold | 2,000 | $173.9K |
| August 18, 2026 | Perry Michael SDirector | Sold | 11,600 | $1M |
| June 15, 2026 | Cohen Matthew GregoryDirector | Received as pay | 11,882 | - |
| May 12, 2026 | Lu HongboDirector | Soldpre-planned (10b5-1) | 2,970 | $228.3K |
| April 23, 2026 | Hamilton James CChief Medical Officer | Soldpre-planned (10b5-1) | 10,000 | $750K |
| April 22, 2026 | Apel Daniel JosephChief Financial Officer | Soldpre-planned (10b5-1) | 3,208 | $224.9K |
| April 22, 2026 | Apel Daniel JosephChief Financial Officer | Soldpre-planned (10b5-1) | 1,157 | $81.5K |
| April 22, 2026 | Apel Daniel JosephChief Financial Officer | Soldpre-planned (10b5-1) | 8,730 | $627.9K |
Who owns ARWR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 9.64% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.2% | May 6, 2026 |
| Vanguard Capital Management13G, passive | 5.05% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 499 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 14,830,553 | -3,330,966 |
| Avoro Capital Advisors LLC | 11,355,555 | +655,556 |
| Fmr LLC | 8,039,804 | +773,152 |
| Vanguard Portfolio Management LLC | 6,351,355 | -794,781 |
| Vanguard Capital Management LLC | 6,110,953 | +78,537 |
| State Street Corp | 5,694,640 | -801,490 |
| Norges Bank | 3,896,536 | new |
| Invesco Ltd. | 3,883,976 | +603,329 |
| Geode Capital Management, LLC | 3,530,612 | -748,216 |
| Fred Alger Management, LLC | 3,301,919 | -40,574 |
| Baker Bros. Advisors LP | 1,992,783 | 0 |
| Siren, L.L.C. | 1,715,476 | +100,000 |
| Vestal Point Capital, LP | 1,575,000 | -700,000 |
| Deerfield Management Company, L.P. | 1,389,055 | -184,242 |
| First Trust Advisors LP | 1,352,918 | +1,203,770 |
| Driehaus Capital Management LLC | 1,350,556 | +160,221 |
| Jupiter Topco LLC | 1,221,596 | new |
| Northern Trust Corp | 1,192,868 | -462,969 |
| Dimensional Fund Advisors LP | 1,181,608 | +573,077 |
| Goldman Sachs Group Inc | 1,150,007 | -589,916 |
Insiders
12 insiders reported holding 5,144,517 shares in total, about $252.1M at the last price.
| Holder | Shares |
|---|---|
| Anzalone Christopher RichardChief Executive Officer, Director | 3,792,739 |
| O'Brien PatrickCOO | 547,408 |
| Hamilton James CChief Medical Officer | 226,958 |
| Apel Daniel JosephChief Financial Officer | 162,905 |
| Perry Michael SDirector | 111,459 |
| Ferrari MauroDirector | 69,053 |
| Waddill William D.Director | 56,563 |
| Lu HongboDirector | 52,012 |
| Ingram Douglas SDirector | 46,215 |
| Vakiener VictoriaDirector | 35,723 |
Questions about ARWR
What does Arrowhead Pharmaceuticals, Inc. do?
Arrowhead Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ARWR. Its shares trade on NASDAQ under the ticker ARWR.
What is Arrowhead Pharmaceuticals, Inc.'s net worth?
Arrowhead Pharmaceuticals, Inc. has a market value (market cap) of $6.9B at the latest share price, and shareholders' equity of $465.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Arrowhead Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $320M on revenue of $669.5M.
How much revenue does Arrowhead Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Arrowhead Pharmaceuticals, Inc. reported revenue of $669.5M. That is 16.8% more than a year earlier.
When did Arrowhead Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Arrowhead Pharmaceuticals, Inc.'s next earnings report?
Arrowhead Pharmaceuticals, Inc.'s next report is expected around November 24, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ARWR with
Follow ARWR
Get an email when Arrowhead Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Arrowhead Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.